NCT03878316View on ClinicalTrials.gov

Intranasal Oxytocin for the Treatment of Alcohol Use Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Alcohol Use DisorderAlcohol Misuse
Interventions
DRUG

Instranasal Oxytocin

Intranasal Oxytocin - concentrated formulation - 35 IU per dose

Trial Locations (4)

21224

Johns Hopkins School of Medicine, Baltimore

22904

University of Virginia, Charlottesville

90095

University of California, Los Angeles

02118

Boston Medical Center, Boston

All Listed Sponsors
lead

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH